---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-069318"
form_type: "8-K"
ticker: "XENE"
cik: "0001582313"
company_name: "Xenon Pharmaceuticals Inc."
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:16:13.776076+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Shareholders approve all proposals at annual meeting including 5.2M share increase to equity plan

## Summary
- All 8 director nominees elected, e.g., Dawn Svoronos 61.5M For vs 4.5M Against; broker non-votes 2.6M.
- Say-on-pay advisory vote approved: 64.0M For, 2.0M Against, 0.01M abstain.
- Equity plan amendments approved to increase share reserve by 5,200,000 common shares: 63.1M For, 2.8M Against.
- KPMG LLP appointed as independent auditor for 2024: 66.7M For, 1.8M Withheld.
- Auditor remuneration authority approved: 65.7M For, 0.39M Against, 0.01M Abstain.

## SEC filing metadata
- accession: 0000950170-24-069318
- form_type: 8-K
- ticker: XENE
- cik: 0001582313
- company_name: Xenon Pharmaceuticals Inc.
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582313/000095017024069318/0000950170-24-069318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582313/000095017024069318/xene-20240604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-069318
- JSON: https://secwatch.observer/filing/0000950170-24-069318.json
- Plain text: https://secwatch.observer/filing/0000950170-24-069318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.